Dupixent €5.7 Billion Surge Masks Payer Squeeze and Indirect Comparison Fragility

Sanofi Reports Strong Q3 2026 Results and Upgrades Full-Year Guidance

Sanofi reported strong financial results for Q3 2026, with net sales growing 14.3% at constant exchange rates (CER) to €14.444 billion and business earnings per share (EPS) increasing 19.6% at CER to €3.55. This performance was primarily driven by robust sales from new pharmaceutical launches, which rose 31.4% to €1.4 billion, and Dupixent, which saw a 34.8% increase to €5.7 billion. The company also announced two regulatory approvals and two regulatory designations, leading to an upgraded full-year 2026 guidance. Sanofi now expects sales to grow by a low-teens percentage and business EPS by a mid-teens percentage at CER for FY 2026.

• Exceptional Financial Growth: Sanofi achieved significant financial milestones in Q3 2026, with overall net sales reaching €14.444 billion, marking a 14.3% increase at CER. Business EPS also demonstrated strong growth, climbing 19.6% at CER to €3.55, reflecting effective cost discipline and strong commercial momentum across its portfolio.
• Key Product Performance: The quarter was bolstered by the continued success of Dupixent, which generated €5.7 billion in sales, a 34.8% increase. Additionally, new pharma launches, including ALTUVIIIO, Ayvakit, and Rezurock, collectively contributed €1.4 billion in sales, growing 31.4%. In contrast, vaccines sales decreased by 6.6% to €3.2 billion due to anticipated phasing.
• Pipeline Advancement and Strategic Expansion: Sanofi's pipeline progressed with two regulatory approvals in rare diseases and vaccines, one regulatory submission acceptance, and two regulatory designations (priority review and PRIME). Strategically, the company expanded its alliance with Regeneron in immunology and partnered with Cheplapharm to simplify its legacy medicines portfolio, aiming to enhance R&D productivity and manage its post-Dupixent trajectory.
• Upgraded Full-Year Guidance: Based on its strong Q3 performance and ongoing momentum, Sanofi upgraded its full-year 2026 guidance. The company now anticipates sales to grow by a low-teens percentage at CER and business EPS to increase by a mid-teens percentage at CER, underscoring confidence in its sustainable and profitable growth strategy.

Dupixent's Safety and Tolerability Across Approved Indications

Published data show dupilumab is generally well tolerated across atopic dermatitis, asthma, chronic obstructive pulmonary disease and chronic rhinosinusitis with nasal polyposis, with ocular surface events and injection-site reactions as the most characteristic adverse events. Most events were mild to moderate in severity, most recovered/resolved, and few led to treatment discontinuation.

• Atopic dermatitis – conjunctivitis signal: In LIBERTY AD ADOL, 17/165 (10.3%) dupilumab-treated versus 4/85 (4.7%) placebo-treated adolescents reported one or more conjunctivitis event, all mild to moderate in severity, with 12 (7.3%) and 4 (4.7%) receiving treatment and 12/17 and 4/4 recovered/resolved during the treatment period. In LIBERTY AD PED-OLE, 12/275 adolescents (4.4%) reported one or more conjunctivitis event, most mild to moderate, with ten receiving treatment and ten recovered/resolved during the study. No patients in these trials discontinued study treatment temporarily or permanently because of conjunctivitis.

• Asthma – low ocular rates and sustained tolerability: In LIBERTY ASTHMA QUEST adolescents, 2/68 (2.9%) dupilumab-treated and 1/39 (2.6%) placebo-treated patients reported one or more conjunctivitis event, all mild to moderate, with all cases recovered/resolved during the study. In TRAVERSE (up to 96 weeks, with follow-up to 148 weeks) the most frequently reported treatment-emergent adverse events were nasopharyngitis (17.5-25.9%), injection-site erythema (2.2-23.4%), and bronchitis (9.3-19.0%), with serious asthma exacerbations (0.5-3.6%) and pneumonia (0.7-2.7%) as the most frequently reported serious adverse events. In the TRAVERSE continuation study (431.7 patient-years, median 309 days), 214 (54.5%) reported at least 1 TEAE, 22 (5.6%) reported serious AEs, and 5 (1.3%) deaths occurred, none considered treatment-related.

• COPD with type 2 inflammation – pooled BOREAS and NOTUS: Treatment-emergent adverse events, serious adverse events, adverse events that led to permanent treatment discontinuation, and adverse events that led to death were similar between dupilumab 300 mg every 2 weeks and placebo added to inhaled corticosteroids, a long-acting β2-agonist, and a long-acting muscarinic antagonist over 52 weeks.

• CRSwNP long-term and injection-site profile: In a retrospective cohort of 224 adults treated up to 4.5 years, 16% experienced side effects, most commonly musculoskeletal complaints, followed by skin reactions and injection site reactions, with 40% extending dosing intervals without loss of efficacy. Injection-site reactions are the most common reported adverse event, with ocular complications including dry eyes, conjunctivitis, blepharitis, keratitis, and ocular pruritus also reported.

• Real-world persistence and comparative ocular tolerability: In Spain, persistence rates were 90%, 80%, 78%, and 73% after 1, 2, 3, and 4-years, with 38 patients (13.5%) discontinuing, mainly due to inefficacy (5.6%) and AEs (1.2%). In Italy (5899 on dupilumab and 769 on tralokinumab), conjunctivitis occurred in 10.76% of dupilumab-treated and 12.61% of tralokinumab-treated patients, with time to onset 35.5 ± 45.2 weeks versus 15.3 ± 14.5 weeks (p<0.0001) and discontinuation or switch due to conjunctivitis 25.4% versus 14.4% (p<0.05).

Expanding Dupixent's Reach: New Indications in Clinical Trials

Dupilumab, a fully human monoclonal antibody that binds IL-4Rα and inhibits signaling of both IL-4 and IL-13, is approved for treatment of asthma, atopic dermatitis, and chronic sinusitis with nasal polyposis. Clinical and real-world studies have also evaluated dupilumab in type 2 asthma subgroups, severe asthma, CRSwNP with NSAID-ERD, IgG4-related disease, and bullous pemphigoid.

Navigating the Competitive Landscape for Dupixent's MoA

Dupilumab, a human anti-IL-4Rα antibody, became the first biologic to receive approval in the United States for the treatment of moderate-to-severe AD in March 2017. Rademikibart (formerly CBP-201), a next-generation human IgG4 kappa monoclonal antibody, blocks IL-4Rα-mediated signal transduction and has been trialled in adults with moderate-to-severe AD.

Dupixent's Broad Reach Powers Sanofi's Strong Performance

Sanofi's impressive Q3 2026 financial results, marked by significant growth in new pharmaceutical launches and a standout performance from Dupixent, signal a pivotal moment for the company and the broader landscape of inflammatory disease treatment. Dupixent, a dual IL-4 and IL-13 receptor antagonist, has become a cornerstone therapy, demonstrating remarkable efficacy and safety across a growing spectrum of type 2 inflammatory conditions. Its success in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and eosinophilic esophagitis highlights the power of targeting fundamental disease pathways.

The drug's ability to address multiple comorbidities simultaneously, such as asthma in patients with CRSwNP, offers a significant advantage, simplifying treatment paradigms and improving overall patient outcomes. Real-world evidence consistently reinforces its clinical trial findings, showing sustained benefits in diverse patient populations, including children and the elderly, and demonstrating favorable cost-effectiveness compared to other biologics in certain indications. This robust body of evidence strengthens Dupixent's position for market access and reimbursement, solidifying its role as a preferred option for clinicians.

However, the pharmaceutical landscape for type 2 inflammatory diseases is rapidly evolving. The emergence of new biologics and Janus kinase (JAK) inhibitors, such as lebrikizumab, tralokinumab, nemolizumab, and upadacitinib, introduces heightened competition. While Dupixent has shown strong comparative efficacy, some newer agents are demonstrating comparable or even numerically superior results in specific endpoints or patient subgroups. For instance, nemolizumab has shown greater efficacy in pruritus-related outcomes in prurigo nodularis, and upadacitinib has performed well in pediatric atopic dermatitis. This competitive pressure necessitates continuous innovation and the generation of robust, long-term comparative data to maintain Dupixent's leadership. Sanofi must strategically invest in studies that further differentiate Dupixent, particularly in terms of durability, impact on disease progression, and benefits in complex, comorbid patient profiles, to navigate this dynamic market effectively.